Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens (WBA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -9.34% in 4 Weeks, Here's Why Walgreens (WBA) Looks Ripe for a Turnaround

Walgreens (WBA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Bears are Losing Control Over Walgreens (WBA), Here's Why It's a 'Buy' Now

Conagra Brands

Schnitzer Steel Industries

Constellation Brands

At Tuesday's opening bell, stocks were trading a bit higher. In the first quarter hour of trading, the Nasdaq traded up by around 0.9%, the S&P 500 up by about 0.4% and the Dow Jones industrials were essentially flat.

Earnings Previews: Conagra, Constellation Brands, Schnitzer Steel, Walgreens

Amgen

Chevron

Dow Inc

Intel

JPMorgan Chase & Co

Merck

Pfizer

AT&T

Verizon

The "Dogs of the Dow" is a strategy of buying the 10 highest yielding stocks in the Dow (or a subset thereof). The yield spread between the Dogs and the Dow as a whole is larger than usual.

Why The Dogs Of The Dow Strategy Will Likely Succeed In 2023

Cisco Systems

iShares Select Dividend ETF

Coca-Cola

ProShares S&P 500 Dividend Aristocrats ETF

SPDR S&P Dividend ETF

Very few investment categories generated a positive return in 2022. Over the years, the Dogs of the Dow strategy has generated mixed results, but in a year like 2022, dividends mattered.

The Dow Stock Dogs Performed In 2022

Eli Lilly

UnitedHealth Group

Are these top health care companies on your radar for 2023?

Good Stocks To Buy For 2023? 3 Healthcare Stocks To Know

Sponsored: Tips for Investing A financial advisor can help you understand the advantages and disadvantages of investment properties.

2023 Dogs of the Dow

To say that 2022 has been a tough year for equities is an understatement, especially given the euphoria of the past two years.

2023's Preliminary Dogs of the Dow

Ford Motor Company

Newmont Mining

These high-octane income stocks, with yields ranging from 4.5% to 6%, have been popular buys among select billionaire investors.

4 High-Yield Dividend Stocks Billionaires Are Aggressively Buying for 2023

Lamb Weston Hlds

Lindsay

WBA stock has come under heavy selling pressure ahead of earnings as the company transforms into a full-service health care provider. The post Sellers Hit WBA Stock Ahead Of Earnings; Lamb Weston Holds Near Highs Amid Bullish Growth appeared first on Investor's Business Daily.

Sellers Hit WBA Stock Ahead Of Earnings; Lamb Weston Holds Near Highs Amid Bullish Growth

Helen of Troy

MSC Industrial Direct

Neogen

RPM International

Simply Good Foods

UniFirst

Similar to 2022, inflation will likely be the main concern in 2023 as well. Along with inflation, the Fed's actions to contain inflation are expected to drive the performance of the financial markets, as well as companies, next year.

These Are the 10 Biggest Companies Reporting Earnings in the First Week of Jan 2023

This year, the winter holidays are on weekends. It means that the markets are open more than normal, and next week it will be busy.

Top 3 large-cap stocks reporting earnings in the first week of 2023

Walgreens' yield is attractive, but is it safe?

Should You Invest in Walgreens for Its 5% Dividend Yield?

Johnson & Johnson

Now's the time to pick up a couple of strong earners for your portfolio.

Invest $5,000 In These 2 Top Dividend Stocks Before the End of the Bear Market

DEERFIELD, Ill.--( BUSINESS WIRE )--Today, Walgreens issued the following statement on the passage of the Integrity, Notification, and Fairness in Online Retail Marketplaces (INFORM) Consumers Act in the U.S. Congressional 2023 omnibus spending package.

Walgreens Applauds Lawmakers for passing the INFORM Consumers Act in 2023 Omnibus Spending Package

Walgreens Boots Alliance Inc (NASDAQ:WBA) is gearing up for its fourth-quarter earnings report, due out in two weeks, before the open on Jan. 5.

Walgreens Boots Alliance: The First Dow Earnings Report of 2023

Within the U.S. Healthcare segment, Walgreens Boots (WBA) is optimistic about the acquisition of CareCentrix.

Walgreens Boots (WBA) Gains From Digital Sales Amid Cost Woes

Goldman Sachs BDC

Kinder Morgan

New York Community Bancorp

Starwood Property

abrdn World Healthcare Fund 

The Dividend Harvesting Portfolio is now generating $713.28 in annual dividends, yielding 7.88%. The Dividend Harvesting portfolio has a 75.53% record of finishing the week in the black since its inception, 71/94 weeks.

Dividend Harvesting Portfolio Week 94 Update: $9,400 Allocated, $713.28 Projected Annual Dividends

Large-cap dividend stock Walgreens is clearly being shunned by Wall Street. That's a potential opportunity.

1 Beaten-Down Dow Stock to Buy Before It Pops

The pharmacy sector in general didn't look too attractive on Hump Day.

Why Walgreens Boots Alliance Stock Caught a Cold Today

Bank of Nova Scotia

British American Tobacco

LyondellBasell Industries

Medifast

In 2023, stock market uncertainties will worsen, rewarding investors who seek cheap dividend stocks. The bigger their discount to their fair value, the more margin of safety the company offers.

7 Ridiculously Cheap Stocks Yielding 5% in 2023

CVS Health

Pharmacy chains CVS Health Corp. and Walgreens Boots Alliance Inc. limited purchase of children's pain drugs as they face supply constraints and high demand with the United States experiencing one of the worst flu season in a decade.

CVS, Walgreens limit purchase of children's pain medicines

Strong track record of returning value to shareholders in the form of dividends. The stock appears to be fairly valued according to the Gordon Growth Model with moderate upside potential.

We Like Walgreens Boots Alliance's Dividends

Walgreens is transforming itself by leveraging its vast store footprint into primary care destinations. Its digital sales are growing impressively and management is focused on achieving billions in annual cost savings.

Walgreens Is Cheap At 8.7x P/E And 5% Yield

Walgreens Boots Alliance has seen its results gradually slide over the past decade. The Boots acquisition missed the mark, and the firm's core business strategy needs some changes.

News for Walgreens Stock (WBA)